Saienko O. S., Chemych M. D.

SERUM CERULOPLASMIN AS A PROGNOSTIC INDICATOR OF LONG COVID

---

Show/Download

About the author:

Saienko O. S., Chemych M. D.

Heading:

CLINICAL AND EXPERIMENTAL MEDICINE

Type of article:

Scientific article

Annotation:

The correlations of serum ceruloplasmin levels in patients with Long COVID (n - 35) with clinical and epidemiological features and the possibility of using indicators to predict the course of the disease were studied. The comparison group consisted of 42 clinically and anamnestically healthy persons. The gender distribution in the groups was uneven, with a predominance of women, which is in line with current research. The majority of respondents at the time of the survey had contracted COVID-19 3-6 months before the survey (49%), which corresponded to the spread of the Omicron strain. Ceruloplasmin in patients with Long COVID (47.86 (39.00-50.00) mg/dl) was 2 times higher than in the comparison group (23.95 (19.00-29.25) mg/dl) (p<0.05). An increase in ceruloplasmin levels was observed in patients with a shorter period after COVID-19 disease, respectively, after 12 months and more, it decreased by 45% compared with 3 months, by 25% - from 3 to 6 months (p<0.05). Ceruloplasmin levels were directly correlated with leukocyte count and total inflammation index in both groups (p<0.05), indicating its involvement in the immune response at the level of other cytokines in patients with Long COVID.

Tags:

Bibliography:

1. Klein J, Wood J, Jaycox JR, Dhodapkar RM, Lu P, Gehlhausen JR, et al. Distinguishing features of long COVID identified through immune profiling. Nature. 2023;623(7985):139-148. DOI: 10.1038/s41586-023-06651-y.
2. The Lancet. Long COVID: 3 years in. Lancet. 2023;401(10379):795. DOI: 10.1016/S0140-6736(23)00493-2.
3. Saienko O, Chemych M. Changes in indicators of endogenous intoxication, nonspecific reactivity, and inflammation caused by SARSCOV-2. East. Ukr. Med. J. 2024;12(2):422-30. Available from: https://eumj.med.sumdu.edu.ua/ index.php/journal/article/view/422-430.
4. Svitailo V, Chemych M. Clinical and epidemiological characteristics of Long-COVID development patterns in patients of different age groups. East. Ukr. Med. J. 2024;12(2):431-40. Available from: https://eumj.med.sumdu.edu.ua/ index.php/journal/article/view/553.
5. Negrut N, Menegas G, Kampioti S, Bourelou M, Kopanyi F, Hassan FD, et al. The Multisystem Impact of Long COVID: A Comprehensive Review. Diagnostics. 2024;14:244. DOI: https://doi.org/10.3390/diagnostics140302 44.
6. Davis HE, McCorkell L, Vogel JM, Topol EJ. Long COVID: major findings, mechanisms and recommendations. Nat Rev Microbiol. 2023;21:133-146. DOI: https://doi.org/10.1038/s41579-022-00846-2.
7. Svitailo VS, Chemych MD, Saienko OS. Long-COVID ta asotsiyovani urazhennya sertsevo-sudynnoyi ta nervovoyi system. Infektsiyni khvoroby. 2023;14(4):49-54. DOI: https://doi.org/10.11603/1681-2727.2022.4.13701. [in Ukrainian].
8. Saienko O, Chemych M, Svitailo V. Long-COVID, neurological and cardiovascular disorders. Journal of Education, Health and Sport. 2023;13(3):381-393. DOI: http://dx.doi.org/10.12775/JEHS.2023.13.03.048.
9. Leng A, Shah M, Ahmad SA, Premraj L, Wildi K, Li Bassi G, et al. Pathogenesis Underlying Neurological Manifestations of Long COVID Syndrome and Potential Therapeutics. Cells. 2023;12(5):816. DOI: 10.3390/cells12050816.
10. Yin K, Peluso MJ, Luo X, Thomas R, Shin MG, Neidleman J, et al. Long COVID manifests with T cell dysregulation, inflammation, and an uncoordinated adaptive immune response to SARS-CoV-2. Preprint. bioRxiv. 2023. DOI: 10.1101/2023.02.09.527892.
11. Boufidou F, Medić S, Lampropoulou V, Siafakas N, Tsakris A, Anastassopoulou C. SARS-CoV-2 Reinfections and Long COVID in the PostOmicron Phase of the Pandemic. Int J Mol Sci. 2023;24(16):12962. DOI: 10.3390/ijms241612962.
12. Reștea P-A, Țigan Ș, Vicaș LG, Fritea L, Marian E, Jurca T, et al. Serum Level of Ceruloplasmin, Angiotensin-Converting Enzyme and Transferrin as Markers of Severity in SARS-CoV-2 Infection in Patients with Type 2 Diabetes. Microbiol. Res. 2023;14:1670-1686. DOI: https://doi.org/10.3390/ microbiolres14040115.
13. Lopez MJ, Royer A, Shah NJ. Biochemistry, Ceruloplasmin. Treasure Island (FL): StatPearls Publishing; 2023.
14. Cheli VT, Sekhar M, Santiago González DA, Angeliu CG, Denaroso GE, Smith Z, et al. The expression of ceruloplasmin in astrocytes is essential for postnatal myelination and myelin maintenance in the adult brain. Glia. 2023;71(10):2323-2342. DOI: 10.1002/glia.24424.
15. Chemych MD, Lishnevska AG. The role of galectin-9 in patients with chronic viral hepatitis C and its connection with the type of therapy, the degree of fibrosis, clinical, laboratory, autoimmune and integrative indicators. Wiad Lek. 2021;74(5):1180-1188.
16. Au L, Capotescu C, Curi A, Gonçalves Leonel da Silva R, Eyal G. Long Covid requires a global response centred on equity and dialogue. Glob Health Action. 2023;16(1):2244757. DOI: 10.1080/16549716.2023.2244757.
17. Ruiyin W, Qi J, Tingting W, Yuqin Y, Yan J, Kun P. Long COVID outcomes following omicron wave in non-hospital population. Front Public Health. 2024;12:1377866. DOI: 10.3389/fpubh.2024.1377866.
18. Hadley E, Yoo YJ, Patel S, Zhou A, Laraway B, Wong R, et al. N3C and RECOVER consortia. SARS-CoV-2 Reinfection is Preceded by Unique Biomarkers and Related to Initial Infection Timing and Severity: An N3C RECOVER EHR-Based Cohort Study. medRxiv. 2023. DOI: 10.1101/2023.01.03.22284042.
19. Fernández-De-Las-Peñas C, Notarte KI, Peligro PJ, Velasco JV, Ocampo MJ, Henry BM, et al. Long-COVID Symptoms in Individuals Infected with Different SARS-CoV-2 Variants of Concern: A Systematic Review of the Literature. Viruses. 2022;14:2629. DOI: 10.3390/ v14122629.
20. Yang C, Zhao H, Shannon CP, Tebbutt SJ. Omicron variants of SARS-CoV-2 and long COVID. Front. Immunol. 2022;13:1061686. DOI: 10.3389/fimmu.2022.1061686.
21. Jain V, Kumar P, Panda PK, Suresh M, Kaushal K, Mirza AA, et al. Utility of IL-6 in the Diagnosis, Treatment and Prognosis of COVID-19 Patients: A Longitudinal Study. Vaccines. 2022;10(11):1786. DOI: https://doi.org/10. 3390/vaccines10111786.
22. Hackler J, Heller RA, Sun Q, Schwarzer M, Diegmann J, Bachmann M, et al. Relation of Serum Copper Status to Survival in COVID-19. Nutrients. 2021;3:1898. DOI: https://doi.org/10.3390/nu13061898.

Publication of the article:

«Bulletin of problems biology and medicine», 2024 Issue 3, 174, 173-179 pages, index UDC 616.98:578.834]-036.22-099-022:612.017:616.152-008.82/.83

DOI:

10.29254/2077-4214-2024-3-174-173-179